Compare OSPN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | LRMR |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.7M | 455.8M |
| IPO Year | 2000 | 2014 |
| Metric | OSPN | LRMR |
|---|---|---|
| Price | $17.83 | $3.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.67 | $16.50 |
| AVG Volume (30 Days) | 312.9K | ★ 858.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $3.16 | $1,816.14 |
| P/E Ratio | $35.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $2.72 |
| 52 Week High | $18.48 | $6.42 |
| Indicator | OSPN | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 43.68 |
| Support Level | $14.86 | $3.57 |
| Resistance Level | $18.48 | $4.21 |
| Average True Range (ATR) | 0.48 | 0.19 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 90.77 | 11.65 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.